Comparability of Five Alternative AAV9 Downstream Processes, from Ultracentrifugation to Chromatography, Upcoming Webinar Hosted by Xtalks

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Comparability of Five Alternative AAV9 Downstream Processes, from Ultracentrifugation to Chromatography, Upcoming Webinar Hosted by Xtalks

PR Newswire

In this webinar, take a deep dive into the downstream manufacturing processes for producing functional adeno-associated virus (AAV) capsids. Attendees will explore the different parameters that set apart ultracentrifugation from chromatography, including drug potency, vector yields, plasmid and host-cell deoxyribonucleic acid (DNA) levels and more. The featured speakers will also analyze scaling differences — how the two-column processes can be more readily scaled to 500-L and 1000-L bioreactors than the UC process.

TORONTO, June 13, 2024 /PRNewswire-PRWeb/ -- Improved analytical methods are helping improve the understanding of capsid heterogeneity in adeno-associated virus (AAV) therapeutic preparations. This understanding allows the development of manufacturing processes that produce AAV therapeutics with fewer non-functional capsids.

Register for this webinar today to gain insights into the production of AAV therapeutics using enhanced analytical methods with their role in reducing capsid heterogeneity.

In this webinar, the speakers will present the results of a five-arm AAV9 comparability protocol that includes four alternative two-column downstream processes at 50-L scale and an ultracentrifugation (UC) process at 200-L scale. The UC process is the gold standard for functional capsid purification.

The expert speakers will outline simplified processes for both the capture and the empty/full (E/F) separation steps, including various combinations of cation exchange chromatography (CEX) and anion exchange chromatography (AEX) monoliths with different gradient types, as well as a process using an affinity resin and AEX monolith.

Also, the speakers will cover the analytical comparability of the drug substance lots, assessment of vector yields, host–cell proteins, plasmid and host-cell deoxyribonucleic acid (DNA) levels; capsid content by sedimentation-velocity analytical UC, charge detection mass spectrometry and mass photometry; vector protein purity by capillary electrophoresis; aggregation by size-exclusion chromatography; vector DNA purity by next-generation sequencing; potency by in vitro enhanced green fluorescent protein (eGFP) expression tests; and capsid protein charge heterogeneity and intact-capsid isoelectric point (pI) by capillary isoelectric focusing.

Register for this webinar today to gain insights into the production of AAV therapeutics using enhanced analytical methods with their role in reducing capsid heterogeneity.

Join Aleš Štrancar, Executive Managing Director, Sartorius BIA Separations, Joe Balleydier, Senior Vice President of Research and Development, Advanced Medicine Partners; and Mike Hatfield, Senior Director of Research and Development, Advanced Medicine Partners, for the live webinar on Thursday, June 27, 2024, at 10am EDT (3pm BST/UK)

For more information, or to register for this event, visit Comparability of Five Alternative AAV9 Downstream Processes, from Ultracentrifugation to Chromatography.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/

Media Contact

Soumya Shashikumar, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com/

Cision View original content to download multimedia:https://www.prweb.com/releases/comparability-of-five-alternative-aav9-downstream-processes-from-ultracentrifugation-to-chromatography-upcoming-webinar-hosted-by-xtalks-302171091.html

SOURCE Xtalks

Copyright CNW Group 2024

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).